- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 16.05. | H.C. Wainwright cuts BiomX stock target to $15, maintains Buy | 6 | Investing.com | ||
| 15.05. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.05. | BiomX GAAP EPS of -$0.33 beats by $0.03 | 7 | Seeking Alpha | ||
| 15.05. | BiomX Inc. Bottom Line Retreats In Q1, But Beats Estimates | 1 | RTTNews | ||
| 15.05. | BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | 70 | GlobeNewswire (Europe) | In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on... ► Artikel lesen | |
| 14.05. | A Look at BiomX's Upcoming Earnings Report | 5 | Benzinga.com | ||
| 23.04. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.04. | BiomX Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 04.04. | H.C. Wainwright maintains BiomX stock Buy rating, $21 target | 12 | Investing.com | ||
| 01.04. | BiomX stock target soars to $21 on Phase 2 trial success | 2 | Investing.com | ||
| 01.04. | BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure | 107 | GlobeNewswire (Europe) | NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies... ► Artikel lesen | |
| 31.03. | BiomX's bacteria-killing virus reduces diabetic bone ulcers in midstage test | 4 | FierceBiotech | ||
| 31.03. | BiomX Reports Positive BX211 Trial Results In Diabetic Foot Osteomyelitis; Plans Phase 2/3 Trial | 1 | RTTNews | ||
| 31.03. | BiomX reports progress in diabetic ulcer treatment | - | Investing.com | ||
| 31.03. | BiomX meldet Fortschritte bei der Behandlung von diabetischen Geschwüren | 3 | Investing.com Deutsch | ||
| 31.03. | BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) | 100 | GlobeNewswire (Europe) | BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from... ► Artikel lesen | |
| 25.03. | BiomX Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BiomX Inc. Full Year Profit Falls | - | RTTNews | ||
| 25.03. | BiomX Inc. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,90 | +0,68 % | BIONTECH mit Kurssprung | Ursache ist eine neue strategische Partnerschaft mit Bristol Myers Squibb. Beide Unternehmen entwickeln und vermarkten gemeinsam das Krebsmedikament BNT327, einen bispezifischen Antikörper. BMS zahlt... ► Artikel lesen | |
| AMGEN | 255,15 | +1,63 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,830 | -1,08 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,170 | -2,66 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,908 | +3,32 % | Here's Why You Should Add PacBio Stock to Your Portfolio Now | ||
| REDHILL BIOPHARMA | 1,960 | +3,16 % | RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency | The Notification Letter has no immediate effect on the Company's listing on the Nasdaq Capital Market at this time, nor are the Company's business operations affected... ► Artikel lesen | |
| FIBROGEN | 0,258 | 0,00 % | FibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update |
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now... ► Artikel lesen | |
| LEXAGENE | 0,084 | 0,00 % | LexaGene Holdings Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| VAXCYTE | 31,000 | +1,97 % | Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | -- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,511 | -0,29 % | Verrica Pharmaceuticals Inc. - 8-K, Current Report | ||
| HOOKIPA PHARMA | 1,580 | 0,00 % | HOOKIPA Pharma Inc. ("HOOKIPA") Statement regarding potential combination for Poolbeg Pharma plc ("Poolbeg") | NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,875 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| QIAGEN | 40,050 | -0,57 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 47,670 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,484 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.